InMed receives Nasdaq notice of bid price deficiency; 180 days to cure

InMed Pharmaceuticals Inc.

Received Nasdaq notice on March 27, 2026; closing bid price below $1.00 for 30 consecutive days (Feb 11–Mar 26).
Must achieve $1.00 or more for 10 consecutive business days within 180 calendar days to regain compliance.
If not cured, may qualify for additional 180-day period, subject to other listing standards and possible reverse split.
No immediate effect on listing; shares continue trading on Nasdaq under symbol INM.
Company monitoring share price and exploring options, including reverse stock split if needed.

item 3.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.